Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Neurofibromatosis 1

• Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
• Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
• Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
• Dosing and Tolerability of Deoxycholic Acid Versus Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas
• A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
• Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study
• MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
• Doxycycline in Cutaneous Schwannoma (NF2)
• HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
• Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
• Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
• A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQ-B3234 in Patients With Type I Neurofibromatosis
• Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Toxicity of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
• A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis
• NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
• Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
• Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
• Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
• Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
• A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
• A Phase II Trial of Poly-ICLC for Low-Grade Gliomas
• Selumetinib Paediatric NF1 Japan Study
• Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1
• Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1
• A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I
• NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
• Innovative Trial for Understanding the Impact of Targeted Therapies in NF2
• Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
• A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
• Pediatric Long-Term Follow-up and Rollover Study
• MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
• A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
• From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1
• Treatment of NF1-related Plexiform Neurofibroma With Trametinib
• Study of Imatinib in Children With Neurofibromatosis and Airway Tumors
• A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants
• Dexmedetomidine and Propofol for Pediatric MRI Sedation
• SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
• Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours
• Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer
• Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas
• Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
• Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
• Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
• Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1
• Interventions for Reading Disabilities in NF1
• Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
• Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
• AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
• Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II
• Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma
• Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
• MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
• PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
• Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T
• Effect of Lamotrigine on Cognition in NF1
• Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1
• Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
• Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
• Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
• Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
• MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
• Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)
• Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
• Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)
• Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
• Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
• Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients
• Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
• Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas
• Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
• Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)
• AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
• Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
• Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas
• Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
• Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
• Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
• Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)
• Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
• PTC299 for Treatment of Neurofibromatosis Type 2
• Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1)
• Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1
• A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
• Medical Treatment of "High-Risk" Neurofibromas
• Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1
• Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
• Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
• A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
• Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
• Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)
• Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
• AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
• Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
• NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate
• Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
• Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas
• Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
• R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas